WallStSmart
PHAR

Pharming Group NV

NASDAQ: PHAR · HEALTHCARE · BIOTECHNOLOGY

$16.36
-0.40% today

Updated 2026-04-29

Market cap
$1.16B
P/E ratio
408.88
P/S ratio
3.07x
EPS (TTM)
$0.04
Dividend yield
52W range
$9 – $21
Volume
0.0M

Pharming Group NV (PHAR) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+180.0%
Last 4 quarters
Revenue YoY growth
-99.9%
Most recent quarter
EPS YoY growth
+1300.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+3.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+9.1%
2025-10-22
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-12$0.07+498.3%$15.88$14.51-8.6%
2025-10-22$0.10+180.0%$13.57$14.81+9.1%
2025-07-31$0.01+180.0%$10.09$10.96+8.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.01$0.07+498.3%$106.39M-99.9%
2025-09-30$-0.13$0.10+180.0%$97.29M+30.0%
2025-06-30$-0.01$0.01+180.0%$93.22M+25.9%
2025-03-31$-0.03$-0.02+12.0%$79.09M+42.3%
2024-12-31$0.01$0.01-41.2%$92.70B+113132.8%
2024-09-30$-0.00$-0.02-512.0%$74.85M+12.3%
2024-06-30$-0.00$-0.02-785.0%$74.03M+34.9%
2024-03-31$0.01$-0.19-2744.3%$55.59M
2023-12-31$0.00$-0.04-1002.2%$81.87M
2023-09-30$0.01$0.01-50.0%$66.66M
2023-06-30$0.01$0.01+0.0%$54.90M

Frequently asked questions

Has Pharming Group NV beaten earnings estimates?
Pharming Group NV has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +180.0% over the last 1 quarters.
How does PHAR stock react to earnings?
PHAR stock has moved an average of +3.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Pharming Group NV's revenue growth rate?
Pharming Group NV reported year-over-year revenue growth of -99.9% in its most recent quarter, with EPS growing +1300.0% year-over-year.